Inclusion Criteria

        Part A Dose Escalation: Patients must have histological or cytological confirmation of a
        solid tumour known to harbour KRAS mutations (e.g., NSCLC, mCRC, pancreatic or
        cholangiocarcinoma), and have progressed despite standard therapy(ies), or are intolerant
        to standard therapy(ies), or have a tumour for which no standard therapy(ies) exists.

        Part B Expansion: Patients in Part B must have measurable disease as measured by Response
        Evaluation Criteria in Solid Tumours (RECIST) criteria version 1.1

        Group 1. Patients must have histological or cytological confirmation of locally advanced or
        metastatic KRASm+ NSCLC, who have failed prior therapy and for whom no current therapy is
        available.

        Group 2. Patients must have histological or cytological confirmation of locally advanced or
        metastatic KRASm+ NSCLC, who have failed prior therapy and for whom no current therapy is
        available. At study entry patients must be clinically suitable for mandatory baseline and
        on-treatment tumour biopsies.

          1. Signed written informed consent

          2. ≥ 18 years old

          3. All patients must have an activating KRAS mutation in tumour tissue samples from a
             prior test conducted by a clinical laboratory that has received international or
             country specific certification. Patients in Part B dosed on the basis of the local
             identification of an activating KRAS mutation, and whose KRAS mutation is not
             confirmed by the central laboratory (with the exception of locally obtained KRAS
             mutation status obtained from the approved tests), will remain on study but may be
             excluded from pharmacodynamic and anti-tumour activity analyses and replaced at the
             Sponsor's discretion. KRAS mutations identified in ctDNA (circulating tumour DNA) from
             blood are not acceptable; only mutations identified from tumour tissue are acceptable.
             Activating mutations may include but are not limited to:

             NSCLC KRAS mutations in codons G12/13, Q61, and A59

             mCRC KRAS mutations in codons G12/13 (Exon 2), Q61, A59 (Exon 3), K117, and A146 (Exon
             4)

             Patient must agree to the collection of archival tumour tissue sample for biomarker
             analysis. If an archived tumour sample is not available a fresh tumour biopsy can be
             used.

          4. Adequate organ system function as indicated by:

               1. Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L

               2. Platelets ≥ 100 x 10^9/L

               3. Haemoglobin ≥ 9g/dL

               4. Activated partial thromboplastin time (aPTT) ≤ 1.5 times the upper limit of
                  normal (ULN)

               5. Total bilirubin ≤ 1.5 mg/dL

               6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 times
                  the ULN if no liver involvement or ≤ 5 times the ULN with liver involvement.

               7. Creatinine ≤ 1.5 times the ULN or creatinine clearance ≥ 60 mL/min as calculated
                  by the Cockcroft-Gault method, or 24 hour measured urine creatinine clearance ≥
                  60 mL/min.

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          6. Life expectancy ≥ 12 weeks

          7. Male patients with female partners of child-bearing potential must be willing to use
             one highly effective form of contraception and must use a condom during their
             participation in this study and for 7 months following the last dose of the study
             drug. Male patients must refrain from donating sperm during their participation in the
             study and at least for 7 months after the last treatment.

          8. Female patients must use a highly effective contraceptive measure from screening until
             18 weeks after the last dose of drug. All methods of contraception (with the exception
             of total abstinence) should be used in combination with the use of a condom by a male
             sexual partner for intercourse. Female patients should not be breast-feeding and must
             have a negative pregnancy test prior to start of dosing if of childbearing potential
             or must have evidence of non-childbearing potential by fulfilling one of the following
             criteria at screening:

        Post-menopausal women defined as aged more than 50 years and amenorrhoeic for at least 12
        months following cessation of all exogenous hormonal treatment.

        Documentation of irreversible surgical sterilisation by hysterectomy, bilateral
        oophorectomy, or bilateral salpingectomy, but not tubal ligation.

        Exclusion Criteria:

          1. Patients who have received chemotherapy, radiotherapy, hormonal therapy, immunotherapy
             or investigational drugs within 21 days or 5 half lives (whichever is shorter) from
             enrolment.

          2. With the exception of alopecia, any unresolved toxicities from prior therapy greater
             than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events
             (CTCAE) Grade 1 at the time of enrolment.

          3. Unresolved immunotherapy-related hepatotoxicity from previous therapy.

          4. Major surgery (excluding placement of vascular access) ≤ 21 days from beginning of the
             enrolment or minor surgical procedures ≤ 7 days. No waiting is required following
             implantable port and catheter placement.

          5. Patients receiving full-dose anti-coagulation therapies.

          6. Has active or prior documented autoimmune disease within the past 2 years with the
             exception of vitiligo, Grave's disease, and/or psoriasis not requiring systemic
             treatment.

          7. Has a history of atypical Haemolytic Uremic Syndrome.

          8. Patients with leptomeningeal metastases.

          9. Previously untreated brain metastases. Patients who have received radiation or surgery
             for brain metastases are eligible if therapy was completed at least 3 weeks prior to
             enrolment and there is no evidence of central nervous system disease progression or
             mild neurologic symptoms, and no requirement for chronic corticosteroid therapy.

         10. Evidence of severe or uncontrolled systemic diseases, including uncontrolled
             hypertension, active bleeding diatheses, or active infection including hepatitis B,
             hepatitis C and human immunodeficiency virus (HIV).

         11. Any of the following cardiac criteria:

               1. Congestive heart failure (CHF) per New York Heart Association (NYHA)
                  classification > Class II.

               2. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.

               3. Unstable angina or new-onset angina.

               4. QT interval (QTcF) >470 ms on screening electrocardiogram (ECG) by Fridericia's
                  formula.

         12. History of hypersensitivity to active or inactive excipients of AZD4785 or drugs with
             a similar chemical structure or class to AZD4785.

         13. Judgment by the Investigator that the patient should not participate in the study if
             the patient is unlikely to comply with study procedures, restrictions and
             requirements.

         14. Psychological, familial, sociological, or geographical conditions that do not permit
             compliance with the protocol.